Biomea Fusion Inc. (BMEA)
BMEA trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BMEA on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001840439 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "There is substantial doubt about our ability to continue as a going concern, and we will require substantial additional capital to finance our operations." | 10-Q 2026-11-10 |
| Cash and burn | $26.4M cash; operating cash flow -$11.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 72,678,080 (2026-10-29); 70,703,639 a year earlier; 35,705,786 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-09-22 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche LLP, San Francisco, California, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $196K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$6.2M | -$8.4M | $26.4M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$8.3M | -$10.0M | $34.8M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$12.4M | -$11.7M | $44.7M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | $4.6M | -$13.9M | $55.8M | No debt tags | Needs four quarters | 10-K 2026-03-24 |
| Q3 2025 2025-09-30 | Not filed | -$16.4M | -$11.6M | $46.6M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$20.7M | -$19.2M | $56.2M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$29.3M | -$25.7M | $35.9M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$29.3M | -$30.0M | $58.3M | No debt tags | Needs four quarters | 10-K 2025-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-22 |
| Latest annual report | 10-K | 2026-03-24 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEF 14A | 2026-04-27 |
Source: SEC EDGAR submissions feed, 292 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +2.6% |
| 1 month | -53.8% |
| 3 months | -54.5% |
| Year to date | -53.1% |
| 1 year | -54.9% |
| From 52-week high | -73.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SER | Serina Therapeutics Inc. | $1.42 | +2.16% | $37.7M |
| HYPD | Hyperion DeFi Inc. | $2.47 | -4.26% | $38.3M |
| GRCE | Grace Therapeutics Inc. | $1.75 | -3.31% | $36.8M |
| ATHE | Alterity Therapeutics Limited | $1.96 | 0.00% | $35.7M |
| VERU | Veru Inc. | $2.08 | -0.48% | $35.5M |
| TELO | Telomir Pharmaceuticals Inc. | $0.4810 | -1.96% | $35.4M |
| OSTX | OS Therapies Incorporated | $0.6807 | -8.63% | $35.4M |
| ALDX | Aldeyra Therapeutics Inc. | $0.6696 | +4.01% | $40.4M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier